Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3229 | Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST) Wiki | 0.58 |
| drug1276 | Fibreoptic Endoscopic Evaluation of Swallowing (FEES) Wiki | 0.58 |
| drug1083 | Dysphagia Handicap Index (DHI) Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2719 | RESP301, a Nitric Oxide generating solution Wiki | 0.58 |
| drug3552 | Videofluoroscopy Wiki | 0.58 |
| drug3217 | Surgical procedures performed under general anesthesia Wiki | 0.58 |
| drug3586 | Voice Symptom Scale (VoiSS) Wiki | 0.58 |
| drug3218 | Survey Wiki | 0.15 |
| drug3138 | Standard of Care Wiki | 0.09 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003680 | Deglutition Disorders NIH | 1.00 |
| D006685 | Hoarseness NIH | 0.58 |
| D055154 | Dysphonia NIH | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001618 | Dysphonia HPO | 0.58 |
| HP:0001621 | Weak voice HPO | 0.58 |
| HP:0001609 | Hoarse voice HPO | 0.58 |
Navigate: Correlations HPO
There are 3 clinical trials
Background: Oropharyngeal dysphagia (OD) is a common complication in/post ICU patients that have been with intubation/mechanical ventilation or with tracheotomies or NG tubes, in patients with acute respiratory infection/pneumonia/respiratory insufficiency with a severe disease needing high concentration of oxygen or noninvasive mechanical ventilation and also in patients discharged from acute hospitals to rehabilitation centers, nursing homes or other facilities. All these situations are common for COVID-19 patients that are currently filling our hospitals due to the pandemic expansion of SARS-CoV-2. OD is associated to prolonged hospitalization, dehydration and severe nutritional and respiratory complications -aspiration pneumonia-, hospital readmissions and mortality. Aim: to assess the prevalence of OD and nutritional risk in these patients and to know their needs of compensatory treatment following the application of an early intervention, and to assess whether OD and malnutrition are indicators of poor prognosis for COVID-19 patients. Methods: prospective study in which we will use the volume-viscosity swallowing test (V-VST) to assess the prevalence of OD, and NRS2002 to assess the nutritional risk in admitted patients with confirmed COVID-19 at the Consorci Sanitari del Maresme, Catalonia, Spain. We will register also results of the EAT-10, nutritional status, the needs of compensatory treatments of these patients following an early intervention with fluid and nutritional adaptation and use of nutritional supplements. We will also collect other clinical variables from medical history of the patient related to hospitalization and we will follow the clinical complications and nutritional status at 3 and 6 months follow up.
Description: Changes in the prevalence of oropharyngeal dysphagia according to a clinical assessment tool, the Volume-Viscosity Swallowing Test (V-VST).
Measure: Changes in the prevalence of oropharyngeal dysphagia Time: From April to December 2020. And at 3 and 6 months follow-up.Description: Changes in the eating assessment tool (EAT-10 score). A tool that goes from 0 to 40 points and indicates that the patient is at risk of oropharyngeal dysphagia if he/she presents 3 or more points
Measure: Changes in the swallowing screening Time: From April to December 2020. And at 3 and 6 months follow-up.Description: Changes in the percentage of patients with impairements in efficacy and/or safety of swallow.
Measure: Changes in the swallowing status Time: From April to December 2020. And at 3 and 6 months follow-up.Description: Changes in the nutritional status of study patients (% malnourished, at risk of malnutrition or wellnourished).
Measure: Changes in the nutritonal status of study patient's. Time: From April to December 2020. And at 3 and 6 months follow-up.Description: Changes in the fluid (volume and viscosity) requirements of study patients.
Measure: Changes in the needs of compensatory treatments in those patients with oropharyngeal dysphagia (fluid adaptation). Time: From April to December 2020. And at 3 and 6 months follow-up.Description: Changes in the nutritional adaptation requirements (type of diet and need of nutritional supplementation).
Measure: Changes in the needs of compensatory treatments in those patients with oropharyngeal dysphagia (nutritional adaptation). Time: From April to December 2020. And at 3 and 6 months follow-up.Description: Changes in the incidence of hospital readmissions: number of hospital readmissions/patient/6 months.
Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (incidence of readmissions). Time: 3 and 6 months from inclusion.Description: Changes in the prevalence: % of patients with hospital readmissions during the follow-up.
Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (prevalence of readmissions). Time: 3 and 6 months from inclusion.Description: Incidence: number of visits to the emergency department/patient/ 3 or 6 months.
Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (number of visits to emergency department). Time: 3 and 6 months from inclusion.Description: Prevalence: % of patients visiting the emergency department during the follow-up.
Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (percentage of visits to emergency department). Time: 3 and 6 months from inclusion.Description: Incidence of respiratory infections (including pneumonia, and COPD exacerbations).
Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (respiratory complications). Time: 3 and 6 months from inclusion.Description: 3 and 6 months mortality.
Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (mortality). Time: 3 and 6 months from inclusion.The current study is aimed to determine the procedures applied in the dysphagia clinics during the COVID-19 pandemic period. A questionnaire consisting of 30 questions will be implemented. Each participant will be asked to answer the questions.
Description: An online survey will be designed to understand the current clinical conditions and current practice regarding dysphagia management during the pandemic period/normalization period
Measure: Online survey Time: 3 monthsThis study examines the presence, severity and natural history of dysphagia and dysphonia in the post-extubation and severely unwell COVID-19 patient.
Description: Based on therapy outcome measures from FEES, VoiS
Measure: Primary endpoint is severity of dysphonia and dysphagia at the time of initial assessment t = day 0 (for ITU patients: Day 0 = 24 hours after extubation or decannulation). Time: t = day 0 (for ITU patients: Day 0 = 24 hours after extubation or decannulation).Description: Clinical assessment including outcome measures, FEES and/or Videofluoroscopy
Measure: The severity of dysphonia and/or dysphagia over an initial 12 month period (at t = 14 days, 1 month, 3 months, 6 months, 9 months, 12 months) Time: t = 14 days, 1 month, 3 months, 6 months, 9 months, 12 monthsDescription: Clinical assessment including outcome measures, FEES and/or Videofluoroscopy
Measure: The severity of dysphonia and/or dysphagia at t = day 5, day 10, day 14, day 21 - For in-patients only. Time: t = day 5, day 10, day 14, day 21 - For in-patients only.Description: Clinical assessment including outcome measures, FEES and/or Videofluoroscopy
Measure: Relationship between severity of dysphonia and/or dysphagia with grade of ARDS Time: t = day 0 and 9 monthsDescription: Clinical assessment including outcome measures, FEES and/or Videofluoroscopy
Measure: Relationship between severity of dysphonia and/or dysphagia with length of intubation Time: t = day 0 and 9 monthsDescription: Clinical assessment including outcome measures, FEES and/or Videofluoroscopy
Measure: Relationship between severity of dysphonia and/or dysphagia with duration of mechanical ventilation Time: t = day 0 and 9 monthsDescription: Questionnaire assessment: This is a 30-item validated quality of life tool that is also a self-reporting tool. It appraises the impact of the patient's abnormal voice from an emotional perspective, related physical symptoms and stratifies the impairment itself in context of day to day activities. VoiSS is currently the most psychometrically robust voice outcome measure. Each item is scored 0 - 4 on the frequency responses: never, occasionally, some of the time, most of the time, always. The total score of 120 measures general voice pathology which is made up of Impairment = maximum score of 60; Emotional = maximum score of 32; Physical = maximum score of 28
Measure: Relationship between severity of dysphonia on quality of life using Voice Symptom Scale (VoiSS) questionnaire over time at day 0, 1 month and 9 months. Time: t = day 0, 1 month and 9 months.Description: Questionnaire assessment: This is a 25-item questionnaire assessing three domains: physical (9 items), functional (9 items), and emotional aspects (7 items) of the Quality of Life (QOL) in patients suffering with dysphagia. For each statement the patient checks if it applies to him/her all the time, some of the time or never. The suggested scores are 0, 2 and 4, respectively. Using this scoring system amounts to a DHI score range of 0 - 100. The higher the score, the worse the dysphagia related QOL. The patient is also asked to provide a rating of their own impression of the severity of the dysphagia experienced on a scale from 1 (normal) to 7 (severe problem).
Measure: Relationship between severity of dysphagia on quality of life using Dysphagia Handicap Index (DHI) questionnaire over time at day 0, 1 month and 9 months Time: t = day 0, 1 month and 9 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports